Skip to content

TriangleGet started

← Full study record

NCT00056160 · BASELINE

Baseline characteristics

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma · Source last updated 2017-10-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
177
group Id
BG001
value
176
group Id
BG002
value
353
units
Participants

groups

description
CC-5013 (lenalidomide) plus oral high-dose dexamethasone
id
BG000
title
CC-5013/Dex
description
Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone
id
BG001
title
Placebo/Dex
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
<=18 years
measurements
group Id
BG000
value
94
group Id
BG001
value
103
group Id
BG002
value
197
title
Between 18 and 65 years
measurements
group Id
BG000
value
83
group Id
BG001
value
73
group Id
BG002
value
156
title
>=65 years
param Type
COUNT_OF_PARTICIPANTS
title
Age, Categorical
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
spread
9.84
value
63.3
group Id
BG001
spread
9.81
value
62.5
group Id
BG002
spread
9.81
value
62.9
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
71
group Id
BG001
value
72
group Id
BG002
value
143
title
Female
measurements
group Id
BG000
value
106
group Id
BG001
value
104
group Id
BG002
value
210
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
142
group Id
BG001
value
150
group Id
BG002
value
292
title
United States
categories
measurements
group Id
BG000
value
35
group Id
BG001
value
26
group Id
BG002
value
61
title
Canada
param Type
NUMBER
title
Region of Enrollment
unit Of Measure
participants

Complete source fields

denoms

counts
group Id
BG000
value
177
group Id
BG001
value
176
group Id
BG002
value
353
units
Participants

groups

description
CC-5013 (lenalidomide) plus oral high-dose dexamethasone
id
BG000
title
CC-5013/Dex
description
Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone
id
BG001
title
Placebo/Dex
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
<=18 years
measurements
group Id
BG000
value
94
group Id
BG001
value
103
group Id
BG002
value
197
title
Between 18 and 65 years
measurements
group Id
BG000
value
83
group Id
BG001
value
73
group Id
BG002
value
156
title
>=65 years
param Type
COUNT_OF_PARTICIPANTS
title
Age, Categorical
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
spread
9.84
value
63.3
group Id
BG001
spread
9.81
value
62.5
group Id
BG002
spread
9.81
value
62.9
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
71
group Id
BG001
value
72
group Id
BG002
value
143
title
Female
measurements
group Id
BG000
value
106
group Id
BG001
value
104
group Id
BG002
value
210
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
142
group Id
BG001
value
150
group Id
BG002
value
292
title
United States
categories
measurements
group Id
BG000
value
35
group Id
BG001
value
26
group Id
BG002
value
61
title
Canada
param Type
NUMBER
title
Region of Enrollment
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice